|

Depression Clinical Trials in Alabama

28 recruiting studies across 6 cities

All Trials in Alabama

Phase
Trial Phase Location
Digital Intervention for Physical ActivityN/AAuburn
Using TMS to Understand Neural Processes of Social MotivationN/AAuburn
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant DepressionN/ABirmingham
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive DisorderPhase 3Birmingham
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderPhase 3Birmingham
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive DisorderPhase 3Birmingham
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant ResponsePhase 2Birmingham
ALTO-100 in Bipolar Disorder With Depression (BD-D)Phase 2Birmingham
Double-blind, Placebo-controlled Study in Adults With Major Depressive DisorderPhase 2Birmingham
Investigating Dynamic Interactions in Distributed Cognitive Control Networks—Birmingham
MicroRNA Correlates of Childhood Maltreatment and Suicidality—Birmingham
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in AdolescentsN/ABirmingham
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia SymptomsPhase 3Birmingham
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant DepressionPhase 3Birmingham
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPhase 2Birmingham
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)Phase 2Birmingham
Transforming Care for Individuals With Childhood-onset Systemic Lupus ErythematosusN/ABirmingham
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)N/ABirmingham
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive DisorderPhase 2Birmingham
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive DisorderPhase 2Dothan
ALTO-207 in Adults With Treatment-resistant Depression (TRD)Phase 2Dothan
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric PatientsPhase 3Dothan
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II DisorderPhase 2Huntsville
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Phase 3Huntsville
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Phase 3Huntsville
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderPhase 3Huntsville
Low Voltage Electrical Stimulation for Depression in Parkinson's PatientsN/AMobile
Strengthening Health and Insight in New EducatorsN/ATuscaloosa

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.